Innate Pharma (NASDAQ:IPHYF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage presently has a $13.00 target price on the stock. Zacks Investment Research’s price target would indicate a potential upside of 12.17% from the stock’s previous close.
According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “
Separately, Leerink Swann restated a “buy” rating on shares of Innate Pharma in a research report on Monday, December 5th.
Innate Pharma (NASDAQ:IPHYF) traded up 0.87% during mid-day trading on Wednesday, hitting $11.59. 2,000 shares of the stock were exchanged. Innate Pharma has a 52-week low of $10.36 and a 52-week high of $16.55. The stock has a 50 day moving average of $14.78 and a 200-day moving average of $13.27. The stock’s market cap is $624.43 million.
Get a free copy of the Zacks research report on Innate Pharma (IPHYF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com